Everest Medicines, a rising star in China’s innovative drug sector, is experiencing significant growth fueled by the success of its blockbuster drug Nefecon and its ambitious foray into mRNA tumor vaccines. Nefecon, the world’s first treatment targeting the source of IgA nephropathy, achieved impressive sales in its first month and is poised for even greater success with potential inclusion on China’s national reimbursement drug list. Everest’s commitment to mRNA technology is evident in its clinical trials for personalized therapeutic vaccines and its ambition to become a leading global biopharmaceutical company.